News
EMD Serono and SiS launch corporate accelerator programme for women’s health innovators

SiS: Women’s Health, the platform accelerating innovation in women’s healthcare, has announced the launch of the EMD Serono Corporate Accelerator (ESCA) programme in conjunction with SiS New York 2025.
This exclusive opportunity connects breakthrough reproductive health innovators with EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S., a global healthcare leader, and M Ventures, their strategic corporate venture arm.
The one-day intensive programme, taking place on May 14th, 2025, during SiS New York, offers selected companies unprecedented access to the global leadership team from Merck KGaA Darmstadt, Germany and M Ventures.
Innovators will participate in private pitch sessions, strategic roundtables, and exclusive networking opportunities with key decision-makers.
Nathan Edwards is Founder of SiS: Women’s Health.
Edwards said: “Building on the success of our Innovation Challenge in London, which led to three pilot partnerships from over 100 evaluated startups, this expanded collaboration represents a significant evolution.
“Having EMD Serono now elevate their commitment by making SiS part of their global innovation scouting network validates our mission to transform the women’s health landscape.”
The programme specifically targets innovations in:
- Infertility
- Endometriosis
- Polycystic Ovary Syndrome (PCOS)
- Ovarian Insufficiency
- Telehealth
- Patient Journey Enhancement
Selected companies will benefit from:
- 30-minute private pitch opportunity with EMD Serono and M Ventures leadership
- EMD Serono-led roundtable discussions addressing key systemic challenges in women’s health
- Exclusive cocktail reception with ESCA participants
Key EMD Serono and M Ventures executives participating include:
- Sebastian Bohl, Vice President, Global Head New Businesses Fertility, Merck KGaA, Darmstadt, Germany
- Margaux Bruneau de La Sall, Senior Manager, Global Business Development, Merck KGaA, Darmstadt, Germany
- Hakan Goker, Managing Director, M Ventures
- Julia Barysheva, Head of Marketing Strategy & Portfolio Planning, EMD Serono
- Jan Möller, Vice President, Head of Global Business Development, Merck KGaA, Darmstadt, Germany
The ESCA program is part of SiS New York 2025, the premier women’s health innovation summit delivering actionable insights for building investable and scalable businesses.
The event features industry-leading speakers, successful case studies, and extensive networking opportunities for innovators, investors, service providers, and multinational corporations.
You can visit the event homepage here.
Important Dates:
- Application Deadline: April 17th, 2025
- Shortlist Announcement: April 25th, 2025
- Programme Date: May 14th, 2025
Interested companies can APPLY HERE.
Menopause
Perimenopause misinformation ‘putting women at risk’
Cancer
Early PET scan could chemo response in aggressive breast cancer – study
News
Femtech World reveals startup of the year shortlist

We are excited unveil the three finalists competing for one of the Femtech World Awards’ most coveted honours: the Startup of the Year Award, sponsored by Future Fertility.
This award celebrates an early-stage company making a bold impact in women’s health through innovation, vision and execution.
The winner will be announced at our virtual ceremony on 19 June, with the decision made by a representative from category sponsor Future Fertility.
Congratulations to the shortlist and thank you to everyone who entered or nominated.
Startup of the Year Shortlist

Hello Inside is the first women’s health AI company to turn daily metabolic signals into outcomes women feel and healthcare systems reimburse.
Women’s health has long been under-researched, and current AI benchmarks fail on women’s health questions roughly sixty percent of the time.
Hello Inside built the architecture to close that gap.
Across four years and 12,000+ validated metabolic profiles, three in four women improve at least one symptom within ninety days.
They lose four kilograms in three months, moving from overweight into the healthy range. In a clinical study with Alisa Vitti’s Flo Living, 91.9 per cent reduced PMS burden within sixty days.


U-Ploid is an early-stage biotechnology company tackling one of the most fundamental challenges in fertility care: the sharp, age-related decline in egg quality that limits outcomes across IVF and egg freezing.
While much of the field focuses on improving assessment and selection, U-Ploid is developing a first-in-class therapeutic approach designed to improve egg quality itself by addressing the biological causes of age-related chromosomal errors.
Supported by strong preclinical evidence and now advancing into human studies, U-Ploid combines scientific rigour, regulatory discipline and long-term vision to help redefine what is possible in fertility care.
News4 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Insight4 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Wellness4 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Opinion3 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Hormonal health4 weeks agoToxins and climate harms having ‘alarming’ effect on fertility, research warns
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Events3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Fertility4 weeks agoResearcher explores weight loss jab impact on PCOS







